Transcode Therapeutics
company
About
TransCode Therapeutics is a pre-clinical biopharmaceutical company.
- 1 - 10
Highlights
Details
- Last Funding Type
- Grant
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 2016
- Number Of Employee
- 1 - 10
- Operating Status
- Active
TransCode Therapeutics is an emerging RNA oncology company committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics. Our lead therapeutic candidate, that we believe has blockbuster potential, targets an RNA molecule which has been shown to be the driver of metastatic disease across multiple tumor types and has been validated pre-clinically in our lab at MGH. Our initial FIH clinical study, for which an eIND filing is planned for Q1 of 2022, is intended to provide positive proof-of-mechanism for the TTX platform.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
—
Transcode Therapeutics has raised a total of
—
in funding over 2 rounds. Their latest funding was raised on
Aug 5, 2021 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 5, 2021 | Grant | — | 1 |
National Institutes of Health
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Transcode Therapeutics is funded by 1 investors.
National Institutes of Health
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Institutes of Health
|
Yes | Grant |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
